Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motexafin Gadolinium in Second Line NSCLC
NCT00129844Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Sep 2005
- Primary completion
- Jun 2007
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of motexafin gadolinium in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pharmacyclics. Primary endpoint: Response Rate. Started Sep 2005; status: completed.
02
Drugs
motexafin gadolinium
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00129844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129844.